The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice

Clozapine-N-oxide (CNO) has long been the ligand of choice for selectively activating Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). However, recent studies have challenged the long-held assertion that CNO is otherwise pharmacologically inert. The present study aimed to 1) determine whether CNO is reverse-metabolized to its parent compound clozapine in mice (as has recently been reported in rats), and 2) determine whether CNO exerts clozapine-like interoceptive stimulus effects in rats and/or mice. Following administration of 10.0 mg/kg CNO, pharmacokinetic analyses replicated recent reports of back-conversion to clozapine in rats and revealed that this phenomenon also occurs in mice. In rats and mice trained to discriminate 1.25 mg/kg clozapine from vehicle, CNO (1.0–20.0 mg/kg) produced partial substitution for the clozapine stimulus on average, with full substitution being detected in some individual animals of both species at doses frequently used to activate DREADDs. The present demonstration that CNO is converted to clozapine and exerts clozapine-like behavioral effects in both mice and rats further emphasizes the need for appropriate control groups in studies employing DREADDs, and highlights the utility of the drug discrimination procedure as a tool with which to screen the off-target effects of novel DREADD agonists.

[1]  M. Jann,et al.  Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. , 1994, Archives internationales de pharmacodynamie et de therapie.

[2]  H. Meltzer,et al.  Discriminative stimulus properties of 1.25 and 5.0 mg/kg doses of clozapine in rats: examination of the role of dopamine, serotonin, and muscarinic receptor mechanisms , 2004, Pharmacology Biochemistry and Behavior.

[3]  M. Jann,et al.  Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  B. Cohen,et al.  Tissue Concentrations of Clozapine and its Metabolites in the Rat , 1993, Neuropsychopharmacology.

[5]  Kyle S. Smith,et al.  Dreadds: Use and Application in Behavioral Neuroscience Section 1: Advantages for Behavioral Neuroscience Dreadds Involve the Use of Receptor Proteins Derived from Targeted Mutagenesis of Endogenous G-protein Coupled Receptor , 2022 .

[6]  L. Wise,et al.  Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats , 2000, Psychopharmacology.

[7]  A. Prus,et al.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies , 2009, Psychopharmacology.

[8]  D. Collier,et al.  Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice , 2000, Journal of psychopharmacology.

[9]  Thomas Wichmann,et al.  Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. , 2017, ACS chemical neuroscience.

[10]  Brandon K. Harvey,et al.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine , 2017, Science.

[11]  D. Weinshenker,et al.  Dopamine β-Hydroxylase Inhibitors Enhance the Discriminative Stimulus Effects of Cocaine in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[12]  B. Roth,et al.  DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. , 2015, Annual review of pharmacology and toxicology.

[13]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[14]  Prachi Khare,et al.  Clozapine N-Oxide Administration Produces Behavioral Effects in Long–Evans Rats: Implications for Designing DREADD Experiments , 2016, eNeuro.

[15]  Xi-Ping Huang,et al.  A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior , 2015, Neuron.

[16]  G. Stöcklin,et al.  Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice. , 1994, Nuclear medicine and biology.

[17]  K. Midha,et al.  Characterization of metabolites of clozapine N-oxide in the rat by micro-column high performance liquid chromatography/mass spectrometry with electrospray interface. , 1996, Journal of pharmaceutical and biomedical analysis.

[18]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[19]  Jian Hua Li,et al.  A chemical-genetic approach to study G protein regulation of β cell function in vivo , 2009, Proceedings of the National Academy of Sciences.

[20]  B. Roth,et al.  Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats , 2016, Neuropsychopharmacology.

[21]  Hyunah Choo,et al.  The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs , 2015, ACS chemical neuroscience.

[22]  J. Bergman,et al.  Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs , 1997, Psychopharmacology.

[23]  H. Bun,et al.  Interspecies variability and drug interactions of clozapine metabolism by microsomes , 1999, Fundamental & clinical pharmacology.

[24]  H. Meltzer,et al.  Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice , 2012, Behavioural pharmacology.

[25]  P. Holmes,et al.  Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine β-Hydroxylase , 2010, Neuropsychopharmacology.